Another notable aspect of our experimental design was the multiplicity of subtype-specific cancer and non-cancer cell lines as model systems, as well as the testing of various, approved and experimental PPARγ agonists and HDAC inhibitors to establish a pharmacological class effect, in order to improve the robustness and reproducibility of our findings. The gene discussed is PPARG; the disease is cancer.